A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas

Trial Profile

A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top